patchy depigmentation in the skin, hair, or both is a symptom of Vitiligo.
The disorder presents with amelanotic, white, and well-demarcated macules or patches surrounded by normal skin, and affects approximately 1% of adults and children globally.
Patients with vitiligo can suffer from stigmatization, which can negatively impact their mental health.
Administering systemic glucocorticoids and phototherapy are some of the traditional therapeutic methods.
Although new therapeutic methods have been tested in clinical trials, they are still not universally effective.
The Pathogenesis of Vitiligo is influenced by the Interferon-Gamma-Chemokine axis.
The progressive melanocyte destruction is the cause of depigmentation.
There is strong evidence that melanocyte-specific CD8+T cells.
After 2 years of treatment, half of the patients had an improvement.
Ruxolitinib was tested as a new treatment in the third phase of the clinical trial.
There are areas of depigmentation in Vitiligo.
According to recent reports, there is a possibility of effective therapy with the use of the JAK inhibitors.
In this case report, we show our experience with an adolescent patient with a long history of generalized and refractory vitiligo who was treated with tofacitinib and phototherapy for 9 months.
The Author(s) will be published in 2021.
S. Karger AG is based in Switzerland.
The progressive disappearance of melanocytes is the cause of Vitiligo, a chronic autoimmune disease.
None of the treatments included in the standard treatment are reliable.
There have been reports and studies that show the benefits of the Jak inhibitors in people.
A case report has been published.
The case of a 17-year-old boy with acrofacial involvement was reported by us.
He denied having a family history of skin conditions.
The previous treatments included oral corticosteroids for 4 years, alternating 6 months each due to unstable vitiligo, and tacrolimus for 6 months.
A 17-year-old boy had a white macule on his forehead, nose, and lips, as well as a single macule above his right clavicle, after 9 months of therapy.
He had done 1 year of phototherapy with no improvement at all, as well as 3 years with little improvement, with the same type of phototherapy.
Considering the high cost of treatment, the patient already started on a combined therapy: tofacitinib 2% + vehicle.
Starting with 200 mJ/ cm2 and increasing by 50 mJ/ cm2 each session, the total dose for the face was 1,000 mJ/ cm2.
The patient underwent a baseline laboratory evaluation before he started on tofacitinib.
The tests showed no abnormality.
His systems were negative in a complete review.
The forehead, nose, eyes, and lips were re-pigmented after 9 months of therapy.
He had some small adverse events.
At baseline in this picture.
The patient had a continuous white macule around his lips and periorbital region.